Inverness Medical raises $3.4 million in sell-off:
This article was originally published in Clinica
Executive Summary
Inverness Medical Technology (formerly known as Selfcare) has sold its minority interest in Theratase, a UK producer of diagnostic enzymes, for £2.2 million ($3.4 million). The UK-based Inverness said that the disposal signifies its focus on blood glucose monitoring and diabetes related products. These are sold in the US through WalMart, Walgreens and other drugstore chains. The company also develops and manufactures proprietary glucose monitoring systems, marketed worldwide through the LifeScan subsidiary of Johnson & Johnson.